Title: Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate,
and tenofovir alafenamide fumarate in patients with hepatitis B: A network meta-analysis
Version: 2 Date: 26 Jul 2023
Reviewer's report:
1. In the methods part of Abstract section, you said "We included all randomized controlled trials
of nucleoside analogues in the treatment of patients with chronic hepatitis B through November
2021". The nucleoside analogues for HBV treatment
include lamivudine, adefovir dipivoxil, entecavir, telbivudine, TDF and TAF. However, the
inclusion should be entecavir, TDF and TAF.
2. In the results part of Abstract section, you said "The probability of three drugs reducing
relevant indicators is, eGFR: TDF(100.0%)#ETV(41.2%)#TAF(8.8%)".  The typeface for ">"
in the manuscript is Song typeface. However, it should be Times New Roman.
3. In the fourth paragraph of Discussion section, you said “However, we found that the effect of
ETV on creatinine was less than that of ETV". You said ETV twice, you should modify it.
4. In the fifth paragraph of Discussion section, you said “We conducted subgroup analysis of
studies that will use two drugs, ETV and TDF".  It should be "used" instead of "will use".
Title: Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate,
and tenofovir alafenamide fumarate in patients with hepatitis B: A network meta-analysis
Version: 2 Date: 26 Jul 2023
Reviewer's report:
1. In the methods part of Abstract section, you said "We included all randomized controlled trials
of nucleoside analogues in the treatment of patients with chronic hepatitis B through November
2021". The nucleoside analogues for HBV treatment
include lamivudine, adefovir dipivoxil, entecavir, telbivudine, TDF and TAF. However, the
inclusion should be entecavir, TDF and TAF.
2. In the results part of Abstract section, you said "The probability of three drugs reducing
relevant indicators is, eGFR: TDF(100.0%)#ETV(41.2%)#TAF(8.8%)".  The typeface for ">"
in the manuscript is Song typeface. However, it should be Times New Roman.
3. In the fourth paragraph of Discussion section, you said “However, we found that the effect of
ETV on creatinine was less than that of ETV". You said ETV twice, you should modify it.
4. In the fifth paragraph of Discussion section, you said “We conducted subgroup analysis of
studies that will use two drugs, ETV and TDF".  It should be "used" instead of "will use".
Please review this paper.
user
Title: Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate,
and tenofovir alafenamide fumarate in patients with hepatitis B: A network meta-analysis
Version: 2 Date: 26 Jul 2023
Reviewer's report:
1. In the methods part of Abstract section, you said "We included all randomized controlled trials
of nucleoside analogues in the treatment of patients with chronic hepatitis B through November
2021". The nucleoside analogues for HBV treatment
include lamivudine, adefovir dipivoxil, entecavir, telbivudine, TDF and TAF. However, the
inclusion should be entecavir, TDF and TAF.
2. In the results part of Abstract section, you said "The probability of three drugs reducing
relevant indicators is, eGFR: TDF(100.0%)#ETV(41.2%)#TAF(8.8%)".  The typeface for ">"
in the manuscript is Song typeface. However, it should be Times New Roman.
3. In the fourth paragraph of Discussion section, you said “However, we found that the effect of
ETV on creatinine was less than that of ETV". You said ETV twice, you should modify it.
4. In the fifth paragraph of Discussion section, you said “We conducted subgroup analysis of
studies that will use two drugs, ETV and TDF".  It should be "used" instead of "will use".
assistant